Sign in

    Sam Nangali

    Research Analyst at Leerink Partners

    Sam Nangali is an Investment Banking Analyst at Leerink Partners, specializing in healthcare investment banking with a focus on supporting transactions and research for companies in the healthcare sector. He has contributed to inquiries and analysis involving specific healthcare firms, including recent work related to MACI Arthro and its performance metrics. Nangali began his career at Leerink Partners and demonstrates a strong foundation in investment banking analysis, leveraging skills that support both transactional execution and sector analysis. His professional background includes advanced training in finance, and he is reported to hold the required securities licenses for his banking role.

    Sam Nangali's questions to Vericel (VCEL) leadership

    Sam Nangali's questions to Vericel (VCEL) leadership • Q1 2025

    Question

    Sam Nangali, on for Mike Kratky, inquired about early data on MACI Arthro conversion rates and their potential impact on second-half growth. He also asked for an update on cross-selling opportunities between Epicel and NexoBrid and whether the integrated sales force had successfully re-engaged any dormant Epicel accounts during the quarter.

    Answer

    CEO Nick Colangelo explained that it is too early to see an inflection in implant conversion rates for MACI Arthro due to the typical 4-to-6-month lag from biopsy to procedure, but an impact is expected in the second half of the year. He confirmed that the company continues to see cross-selling success, securing biopsies from previously dormant accounts, and that converting all centers to use both Epicel and NexoBrid remains a key long-term growth driver for the burn care franchise.

    Ask Fintool Equity Research AI